News & Perspective

Jan 04, 2010

Jan 04, 2010

Three H1N1 vaccine studies confirm safety, weigh dosing

(CIDRAP News) – Large trials in three countries—the United States, Hungary, and China—recently confirmed the safety and efficacy of H1N1 vaccines, yielding new insights on how to best use vaccines in a pandemic setting.

Feb 18, 2010

Feb 18, 2010

WHO picks pandemic strain for next seasonal flu vaccine

(CIDRAP News) – Given signs that the pandemic H1N1 virus will continue its dominance over other flu strains, the World Health Organization (WHO) today recommended adding the pandemic strain as the H1N1 component of the seasonal flu vaccine for the Northern Hemisphere's next flu season.

Feb 22, 2010

Feb 22, 2010

FDA selects pandemic H1N1 for 2010-11 seasonal flu vaccine

(CIDRAP News) – The US Food and Drug Administration's (FDA's) vaccines committee voted today to follow the World Health Organization's advice and fold the pandemic H1N1 influenza vaccine into the seasonal flu vaccine for next season.

Apr 09, 2010

Apr 09, 2010

WHO: Some African, tropical regions show more H1N1

(CIDRAP News) – Though pandemic flu activity stayed stable in most parts of the world, Chile is reporting new detections of the pandemic virus in at least three regions in advance of the start of its flu season, with other hot spots occurring in Bangladesh and parts of Africa, the World Health Organization (WHO) reported today.

May 21, 2010

May 21, 2010

WHO: Pandemic showed limits of vaccine production capacity

(CIDRAP News) – Global production of the H1N1 influenza vaccine has made clear that the world still has a long way to go to meet pandemic production capacity goals set by the World Health Organization (WHO) 4 years ago, WHO experts said in a report released this week.

Pages

Sort Results By:

 Sort Results By:

Narrow results by:

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation Gilead 
Grant support for ASP provided by


bioMérieux

  Become an underwriter»